Critical Evaluation of Toxicity Tests

Adverse Effects of Engineered Nanomaterials

Volumn , Issue , 2012, Pages 63-83

  Dusinska, Maria ^a   Rundén Pran, Elise ^a   Carreira, Sara Correia ^b   Saunders, Margaret ^b  

^a NORWEGIAN INSTITUTE FOR AIR RESEARCH   (Norway)

^b ST MICHAEL'S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84875762982     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-386940-1.00004-0     Document Type: Chapter

References (93)

1. Donaldson K., Stone V., Tran C.L., Kreyling W., Borm P.J. Nanotoxicology. Occup Environ Med 2004, 61:727-728.
2. Haynes C.L. The emerging field of nanotoxicology. Anal Bioanal Chem 2010, 398:587-588.
3. Maynard A.D., Warheit D.B., Philbert M.A. The new toxicology of sophisticated materials: Nanotoxicology and beyond. Toxicol Sci 2011, 120(Suppl. 1):S109-S129.
4. Seaton A., Tran L., Aitken R., Donaldson K. Nanoparticles, human health hazard and regulation. J R Soc Interface 2010, 7(Suppl. 1):S119-S129.
5. Feliu N., Fadeel B. Nanotoxicology: No small matter. Nanoscale 2010, 2:2514-2520.
6. Kroll A., Pillukat M.H., Hahn D., Schnekenburger J. Current in vitro methods in nanoparticle risk assessment: Limitations and challenges. Eur J Pharm Biopharm 2009, 72:370-377.
7. Gwinn M.R., Tran L. Risk management of nanomaterials. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010, 2:130-137.
8. Dusinska M., Fjellsbo L., Magdolenova Z., et al. Testing strategies for the safety of nanoparticles used in medical applications. Nanomedicine (Lond) 2009, 4:605-607.
9. Simko M., Mattsson M.O. Risks from accidental exposures to engineered nanoparticles and neurological health effects: A critical review. Part Fibre Toxicol 2010, 7:42.
10. Schleh C., Semmler-Behnke M., Lipka J., et al. Size and surface charge of gold nanoparticles determine absorption across intestinal barriers and accumulation in secondary target organs after oral administration. Nanotoxicology 2011, [Epub ahead of print].
11. Lehr C.M., Daum N., Schneider M., Schafer U.F. Biological barriers-a need for novel tools in nanotoxicology and nanomedicine. Preface Eur J Pharm Biopharm 2011, 77:337.
12. Warheit D.B., Sayes C.M., Reed K.L., Swain K.A. Health effects related to nanoparticle exposures: Environmental, health and safety considerations for assessing hazards and risks. Pharmacol Ther 2008, 120:35-42.
13. Kunzmann A., Andersson B., Thurnherr T., Krug H., Scheynius A., Fadeel B. Toxicology of engineered nanomaterials: Focus on biocompatibility, biodistribution and biodegradation. Biochim Biophys Acta 2011, 1810:361-373.
14. Dhawan A., Sharma V. Toxicity assessment of nanomaterials: Methods and challenges. Anal Bioanal Chem 2010, 398:589-605.
15. Borm P.J., Muller-Schulte D. Nanoparticles in drug delivery and environmental exposure: Same size, same risks?. Nanomedicine (Lond) 2006, 1:235-249.
16. Oberdorster G., Oberdorster E., Oberdorster J. Nanotoxicology: An emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 2005, 113:823-839.
17. Garza-Ocanas L., Ferrer D.A., Burt J., et al. Biodistribution and long-term fate of silver nanoparticles functionalized with bovine serum albumin in rats. Metallomics 2010, 2:204-210.
18. Monteiro-Riviere N.A., Nemanich R.J., Inman A.O., Wang Y.Y., Riviere J.E. Multi-walled carbon nanotube interactions with human epidermal keratinocytes. Toxicol Lett 2005, 155:377-384.
19. Wang Y., Wang J., Wu M., et al. Internalization, translocation and biotransformation of silica-coated titanium dioxide nanoparticles in neural stem cells. J Nanosci Nanotechnol 2010, 10:7121-7125.
20. Raemy D.O., Limbach L.K., Rothen-Rutishauser B., et al. Cerium oxide nanoparticle uptake kinetics from the gas-phase into lung cells in vitro is transport limited. Eur J Pharm Biopharm 2011, 77:368-375.
21. Thurn K.T., Arora H., Paunesku T., et al. Endocytosis of titanium dioxide nanoparticles in prostate cancer PC-3M cells. Nanomedicine 2011, 7:123-130.
22. Kuo Y.C., Chen H.H. Effect of electromagnetic field on endocytosis of cationic solid lipid nanoparticles by human brain-microvascular endothelial cells. J Drug Target 2010, 18:447-456.
23. Shah N.B., Dong J., Bischof J.C. Cellular uptake and nanoscale localization of gold nanoparticles in cancer using label-free confocal Raman microscopy. Mol Pharm 2011, 8:176-184.
24. Xu P., Gullotti E., Tong L., et al. Intracellular drug delivery by poly(lactic-co-glycolic acid) nanoparticles, revisited. Mol Pharm 2009, 6:190-201.
25. Al Faraj A., Fauvelle F., Luciani N., et al. In vivo biodistribution and biological impact of injected carbon nanotubes using magnetic resonance techniques. Int J Nanomed 2011, 6:351-361.
26. Trickler W.J., Lantz S.M., Murdock R.C., et al. Silver nanoparticle induced blood-brain barrier inflammation and increased permeability in primary rat brain microvessel endothelial cells. Toxicol Sci 2010, 118:160-170.
27. Ragnaill M.N., Brown M., Ye D., et al. Internal benchmarking of a human blood-brain barrier cell model for screening of nanoparticle uptake and transcytosis. Eur J Pharm Biopharm 2011, 77:360-367.
28. Chen J., Dong X., Xin Y., Zhao M. Effects of titanium dioxide nano-particles on growth and some histological parameters of zebrafish ( Danio rerio) after a long-term exposure. Aquat Toxicol 2011, 101:493-499.
29. Seo J.H., Cho K., Lee S.Y., Joo S.W. Concentration-dependent fluorescence live-cell imaging and tracking of intracellular nanoparticles. Nanotechnology 2011, 22:235101.
30. Liu F., Soares M.J., Audus K.L. Permeability properties of monolayers of the human trophoblast cell line BeWo. Am J Physiol 1997, 273:C1596-C1604.
31. Ampasavate C., Chandorkar G.A., Vande Velde D.G., Stobaugh J.F., Audus K.L. Transport and metabolism of opioid peptides across BeWo cells, an in vitro model of the placental barrier. Int J Pharm 2002, 233:85-98.
32. Saunders M. Transplacental transport of nanomaterials. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009, 1:671-684.
33. Brown J., Reading S.J., Jones S., et al. Critical evaluation of ECV304 as a human endothelial cell model defined by genetic analysis and functional responses: A comparison with the human bladder cancer derived epithelial cell line T24/83. Lab Invest 2000, 80:37-45.
34. Saovapakhiran A., D'Emanuele A., Attwood D., Penny J. Surface modification of PAMAM dendrimers modulates the mechanism of cellular internalization. Bioconjug Chem 2009, 20:693-701.
35. Li S.D., Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 2008, 5:496-504.
36. Zheng J., Jaffray D., Allen C. Quantitative CT imaging of the spatial and temporal distribution of liposomes in a rabbit tumor model. Mol Pharm 2009, 6:571-580.
37. Skotland T., Iversen T.G., Sandvig K. New metal-based nanoparticles for intravenous use: Requirements for clinical success with focus on medical imaging. Nanomedicine 2010, 6:730-737.
38. Robe A., Pic E., Lassalle H.P., Bezdetnaya L., Guillemin F., Marchal F. Quantum dots in axillary lymph node mapping: Biodistribution study in healthy mice. BMC Cancer 2008, 8:111.
39. Tasciotti E., Godin B., Martinez J.O., et al. Near-infrared imaging method for the in vivo assessment of the biodistribution of nanoporous silicon particles. Mol Imaging 2011, 10:56-68.
40. Burns A.A., Vider J., Ow H., et al. Fluorescent silica nanoparticles with efficient urinary excretion for nanomedicine. Nano Lett 2009, 9:442-448.
41. Vaccaro D.E., Yang M., Weinberg J.S., Reinhardt C.P., Groman E.V. Cell tracking using nanoparticles. J Cardiovasc Transl Res 2008, 1:217-220.
42. Stelter L., Pinkernelle J.G., Michel R., et al. Modification of aminosilanized superparamagnetic nanoparticles: Feasibility of multimodal detection using 3T MRI, small animal PET, and fluorescence imaging. Mol Imaging Biol 2010, 12:25-34.
43. Wang Y., Seebald J.L., Szeto D.P., Irudayaraj J. Biocompatibility and biodistribution of surface-enhanced Raman scattering nanoprobes in zebrafish embryos: In vivo and multiplex imaging. ACS Nano 2010, 4:4039-4053.
44. Federici G., Shaw B.J., Handy R.D. Toxicity of titanium dioxide nanoparticles to rainbow trout ( Oncorhynchus mykiss): Gill injury, oxidative stress, and other physiological effects. Aquat Toxicol 2007, 84:415-430.
45. Runden E., Seglen P.O., Haug F.M., et al. Regional selective neuronal degeneration after protein phosphatase inhibition in hippocampal slice cultures: Evidence for a MAP kinase-dependent mechanism. J Neurosci 1998, 18:7296-7305.
46. Noraberg J. Organotypic brain slice cultures: An efficient and reliable method for neurotoxicological screening and mechanistic studies. Altern Lab Anim 2004, 32:329-337.
47. Ring A., Tanso R., Noraberg J. The use of organotypic hippocampal slice cultures to evaluate protection by non-competitive NMDA receptor antagonists against excitotoxicity. Altern Lab Anim 2010, 38:71-82.
48. Prestwich G.D. Evaluating drug efficacy and toxicology in three dimensions: Using synthetic extracellular matrices in drug discovery. Acc Chem Res 2008, 41:139-148.
49. Legendre A., Froment P., Desmots S., Lecomte A., Habert R., Lemazurier E. An engineered 3D blood-testis barrier model for the assessment of reproductive toxicity potential. Biomaterials 2010, 31:4492-4505.
50. Abbott A. Cell culture: Biology's new dimension. Nature 2003, 424:870-872.
51. Lee J., Lilly G.D., Doty R.C., Podsiadlo P., Kotov N.A. In vitro toxicity testing of nanoparticles in 3D cell culture. Small 2009, 5:1213-1221.
52. Derda R., Laromaine A., Mammoto A., et al. Paper-supported 3D cell culture for tissue-based bioassays. Proc Natl Acad Sci USA 2009, 106:18457-18462.
53. Huh D., Matthews B.D., Mammoto A., Montoya-Zavala M., Hsin H.Y., Ingber D.E. Reconstituting organ-level lung functions on a chip. Science 2010, 328:1662-1668.
54. Byrne H.J., Lynch I., de Jong W.H., et al. Protocols for assessment of biological hazards of engineered nanoparticles. Eur Network Health Environ Impact Nanomaterials 2010, report on. http://www.nanoimpact.eu.
55. Priya B.R., Byrne H.J. Investigation of sodium dodecyl benzene sulphonate assisted dispersion and debundling of single wall carbon nanotubes. J Phys Chem C 2008, 12:332-337.
56. Herzog E., Casey A., Lyng F.M., Chambers G., Byrne H.J., Davoren M. A new approach to the toxicity testing of carbon-based nanomaterials-the clonogenic assay. Toxicol Lett 2007, 174:49-60.
57. Ng C.T., Li J.J., Bay B.H., Yung L.Y. Current studies into the genotoxic effects of nanomaterials. J Nucl Acids 2010, pii: 947859.
58. Mortelmans K., Zeiger E. The Ames Salmonella/microsome mutagenicity assay. Mutat Res 2000, 455:29-60.
59. Shinohara N., Matsumoto K., Endoh S., Maru J., Nakanishi J. In vitro and in vivo genotoxicity tests on fullerene C60 nanoparticles. Toxicol Lett 2009, 191:289-296.
60. Mori T., Takada H., Ito S., Matsubayashi K., Miwa N., Sawaguchi T. Preclinical studies on safety of fullerene upon acute oral administration and evaluation for no mutagenesis. Toxicology 2006, 225:48-54.
61. Wirnitzer U., Herbold B., Voetz M., Ragot J. Studies on the in vitro genotoxicity of baytubes, agglomerates of engineered multi-walled carbon-nanotubes (MWCNT). Toxicol Lett 2009, 186:160-165.
62. Di Sotto A., Chiaretti M., Carru G.A., Bellucci S., Mazzanti G. Multi-walled carbon nanotubes: Lack of mutagenic activity in the bacterial reverse mutation assay. Toxicol Lett 2009, 184:192-197.
63. Balasubramanyam A., Sailaja N., Mahboob M., Rahman M.F., Hussain S.M., Grover P. In vitro mutagenicity assessment of aluminium oxide nanomaterials using the Salmonella/microsome assay. Toxicol In Vitro 2010, 24:1871-1876.
64. Maenosono S., Suzuki T., Saita S. Mutagenicity of water-soluble FePt nanoparticles in Ames test. J Toxicol Sci 2007, 32:575-579.
65. Maenosono S., Yoshida R., Saita S. Evaluation of genotoxicity of amine-terminated water-dispersible FePt nanoparticles in the Ames test and in vitro chromosomal aberration test. J Toxicol Sci 2009, 34:349-354.
66. Yoshida R., Kitamura D., Maenosono S. Mutagenicity of water-soluble ZnO nanoparticles in Ames test. J Toxicol Sci 2009, 34:119-122.
67. Landsiedel R., Kapp M.D., Schulz M., Wiench K., Oesch F. Genotoxicity investigations on nanomaterials: methods, preparation and characterization of test material, potential artifacts and limitations-many questions, some answers. Mutat Res 2009, 681:241-258.
68. Collins A.R., Dusinska M., Gedik C.M., Stetina R. Oxidative damage to DNA: Do we have a reliable biomarker?. Environ Health Perspect 1996, 104(Suppl. 3):465-469.
69. Dusinska M., Collins A.R. Detection of oxidised purines and UV-induced photoproducts in DNA, by inclusion of lesion-specific enzymes in the comet assay (single cell gel electrophoresis). Altern Lab Anim 1996, 24:405-411.
70. Jha A.N. Ecotoxicological applications and significance of the comet assay. Mutagenesis 2008, 23:207-221.
71. OECD. Guidelines for testing chemicals. Mammalian erythrocyte micronucleus test, Vol. Guideline; 1997;474.
72. Laingam S., Froscio S.M., Humpage A.R. Flow-cytometric analysis of in vitro micronucleus formation: Comparative studies with WIL2-NS human lymphoblastoid and L5178Y mouse lymphoma cell lines. Mutat Res 2008, 656:19-26.
73. Fenech M., Kirsch-Volders M., Natarajan A.T., et al. Molecular mechanisms of micronucleus, nucleoplasmic bridge and nuclear bud formation in mammalian and human cells. Mutagenesis 2011, 26:125-132.
74. Doak S.H., Griffiths S.M., Manshian B., et al. Confounding experimental considerations in nanogenotoxicology. Mutagenesis 2009, 24:285-293.
75. Gonzalez L., Sanderson B.J., Kirsch-Volders M. Adaptations of the in vitro MN assay for the genotoxicity assessment of nanomaterials. Mutagenesis 2011, 26:185-191.
76. Fenech M. Cytokinesis-block micronucleus cytome assay. Nat Protoc 2007, 2:1084-1104.
77. Hackenberg S., Scherzed A., Kessler M., et al. Silver nanoparticles: Evaluation of DNA damage, toxicity and functional impairment in human mesenchymal stem cells. Toxicol Lett 2011, 201:27-33.
78. Galloway S.M., Aardema M.J., Ishidate M., et al. Report from working group on in vitro tests for chromosomal aberrations. Mutat Res 1994, 312:241-261.
79. Galloway S.M., Armstrong M.J., Reuben C., et al. Chromosome aberrations and sister chromatid exchanges in Chinese hamster ovary cells: Evaluations of 108 chemicals. Environ Mol Mutagen 1987, 10(Suppl. 10):1-175.
80. Magdolenova Z, Dhawan A, Collins A, Dusinska M. (submitted). Review on nanoparticle genotoxicity. J Biomedical Nanotechnol.
81. Singh N., Manshian B., Jenkins G.J., et al. NanoGenotoxicology: The DNA damaging potential of engineered nanomaterials. Biomaterials 2009, 30:3891-3914.
82. Clift M.J., Gehr P., Rothen-Rutishauser B. Nanotoxicology: A perspective and discussion of whether or not in vitro testing is a valid alternative. Arch Toxicol 2011, 85:723-731.
83. Commitee E.S. Guidance on the risk assessment of the application of nanoscience and nanotechnologies in the food and feed chain. EFSA J 2011, 9:2140-2176.
84. Fischer H.C., Chan W.C. Nanotoxicity: The growing need for in vivo study. Curr Opin Biotechnol 2007, 18:565-571.
85. Ema M., Kobayashi N., Naya M., Hanai S., Nakanishi J. Reproductive and developmental toxicity studies of manufactured nanomaterials. Reprod Toxicol 2010, 30:343-352.
86. Savolainen K., Alenius H., Norppa H., Pylkkanen L., Tuomi T., Kasper G. Risk assessment of engineered nanomaterials and nanotechnologies-a review. Toxicology 2010, 269:92-104.
87. Sayes C.M., Warheit D.B. Characterization of nanomaterials for toxicity assessment. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009, 1:660-670.
88. Khlebtsov N., Dykman L. Biodistribution and toxicity of engineered gold nanoparticles: A review of in vitro and in vivo studies. Chem Soc Rev 2011, 40:1647-1671.
89. Sayes C.M., Reed K.L., Warheit D.B. Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles. Toxicol Sci 2007, 97:163-180.
90. Tang M., Zhang T., Xue Y., et al. Dose dependent in vivo metabolic characteristics of titanium dioxide nanoparticles. J Nanosci Nanotechnol 2010, 10:8575-8583.
91. Canady R.A. The uncertainty of nanotoxicology: Report of a Society for Risk Analysis Workshop. Risk Anal 2010, 30:1663-1670.
92. George S., Xia T., Rallo R., et al. Use of a high-throughput screening approach coupled with in vivo zebrafish embryo screening to develop hazard ranking for engineered nanomaterials. ACS Nano 2011, 5:1805-1817.
93. Poma A., Di Giorgio M.L. Toxicogenomics to improve comprehension of the mechanisms underlying responses of in vitro and in vivo systems to nanomaterials: A review. Curr Genomics 2008, 9:571-585.